TR200200913T2 - Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. - Google Patents

Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.

Info

Publication number
TR200200913T2
TR200200913T2 TR2002/00913T TR200200913T TR200200913T2 TR 200200913 T2 TR200200913 T2 TR 200200913T2 TR 2002/00913 T TR2002/00913 T TR 2002/00913T TR 200200913 T TR200200913 T TR 200200913T TR 200200913 T2 TR200200913 T2 TR 200200913T2
Authority
TR
Turkey
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba analog
Prior art date
Application number
TR2002/00913T
Other languages
English (en)
Inventor
Hughes John
Singh Lakhbir
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR200200913T2 publication Critical patent/TR200200913T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut bulus bir NK1 reseptörü antagonistinin ve bir GABA analogunun sinerjik kombinasyonlarinin kullanildigi bir tedavi ve NK1 reseptörü antagonistini ve GABA analogunu içeren farmasötik bilesimler ve ürünler saglamaktadir. Mevcut bulus ayrica kronik agrinin önlenmesi veya tedavi edilmesi için olan bir ilacin hazirlanmasinda bir NK1 reseptörü antagonistinin ve bir GABA analogunun kullanimi saglamaktadir.
TR2002/00913T 1999-10-07 2000-10-05 Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. TR200200913T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
TR200200913T2 true TR200200913T2 (tr) 2002-09-23

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00913T TR200200913T2 (tr) 1999-10-07 2000-10-05 Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.

Country Status (38)

Country Link
EP (2) EP1221950B1 (tr)
JP (2) JP2003510356A (tr)
KR (1) KR20020060192A (tr)
CN (1) CN1387434A (tr)
AP (1) AP2002002501A0 (tr)
AR (1) AR029646A1 (tr)
AT (1) ATE269072T1 (tr)
AU (2) AU7663300A (tr)
BG (1) BG106548A (tr)
BR (1) BR0014598A (tr)
CA (1) CA2385930A1 (tr)
CO (1) CO5280195A1 (tr)
CR (1) CR6614A (tr)
CZ (1) CZ20021116A3 (tr)
DE (1) DE60011650T2 (tr)
DK (1) DK1221950T3 (tr)
EA (1) EA004266B1 (tr)
EE (1) EE200200185A (tr)
ES (1) ES2220542T3 (tr)
GT (1) GT200000166A (tr)
HR (1) HRP20020286A2 (tr)
HU (1) HUP0203466A3 (tr)
IL (1) IL148965A0 (tr)
IS (1) IS6318A (tr)
MA (1) MA26826A1 (tr)
MX (1) MXPA02003484A (tr)
NO (1) NO20021625D0 (tr)
NZ (1) NZ517949A (tr)
OA (1) OA12063A (tr)
PA (1) PA8504301A1 (tr)
PE (1) PE20010708A1 (tr)
PL (1) PL357498A1 (tr)
PT (1) PT1221950E (tr)
SK (1) SK4542002A3 (tr)
TR (1) TR200200913T2 (tr)
UY (1) UY26376A1 (tr)
WO (2) WO2001024792A1 (tr)
ZA (1) ZA200202675B (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
EP1558218A1 (en) * 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
PL2599487T3 (pl) 2010-07-30 2015-09-30 Toray Industries Środek terapeutyczny lub środek profilaktyczny przeciwko bólowi neuropatycznemu
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
ES2220542T3 (es) 2004-12-16
EP1221950B1 (en) 2004-06-16
CR6614A (es) 2003-12-04
ATE269072T1 (de) 2004-07-15
MA26826A1 (fr) 2004-12-20
NZ517949A (en) 2003-08-29
HRP20020286A2 (en) 2003-08-31
BG106548A (en) 2002-12-29
DE60011650D1 (de) 2004-07-22
PA8504301A1 (es) 2002-08-26
EA200200303A1 (ru) 2002-08-29
WO2001024792A1 (en) 2001-04-12
ZA200202675B (en) 2003-04-15
EP1221950A1 (en) 2002-07-17
BR0014598A (pt) 2002-06-11
EE200200185A (et) 2003-04-15
AR029646A1 (es) 2003-07-10
AU1696201A (en) 2001-05-10
IS6318A (is) 2002-03-21
UY26376A1 (es) 2000-12-29
OA12063A (en) 2006-05-03
PL357498A1 (en) 2004-07-26
AU7663300A (en) 2001-05-10
CZ20021116A3 (cs) 2003-05-14
KR20020060192A (ko) 2002-07-16
WO2001024791A1 (en) 2001-04-12
CN1387434A (zh) 2002-12-25
JP2003510355A (ja) 2003-03-18
CO5280195A1 (es) 2003-05-30
HUP0203466A3 (en) 2005-03-29
CA2385930A1 (en) 2001-04-12
EP1233766A1 (en) 2002-08-28
HUP0203466A2 (hu) 2003-02-28
NO20021625L (no) 2002-04-05
MXPA02003484A (es) 2004-09-10
DK1221950T3 (da) 2004-09-20
SK4542002A3 (en) 2003-09-11
IL148965A0 (en) 2002-11-10
EA004266B1 (ru) 2004-02-26
AP2002002501A0 (en) 2002-06-30
JP2003510356A (ja) 2003-03-18
DE60011650T2 (de) 2005-07-14
PT1221950E (pt) 2004-08-31
GT200000166A (es) 2002-03-30
WO2001024792A9 (en) 2002-09-06
PE20010708A1 (es) 2001-07-27
NO20021625D0 (no) 2002-04-05

Similar Documents

Publication Publication Date Title
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
TR200201067T2 (tr) Bir tramadol maddesi ve bir antikonvülsan ilaç içeren bileşimler
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
AP2000001785A0 (en) Medicaments
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
TW200633978A (en) 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists
BRPI0410049A (pt) composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
AU7226301A (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
TR200200913T2 (tr) Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları.
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
IL133632A (en) Use of a specific 5ht2 receptor antagonist for the preparation of pharmaceutical compositions useful in the treatment of the sleep apnea syndrome
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
BR0007686A (pt) Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda
HK1072012A1 (en) 5-ht4 receptor antagonists for the treatment of heart failure
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
RS60604A (en) Carboxamidine derivatives and their use in the treatment of vascular diseases
BG105984A (bg) Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
BR0113886A (pt) Composição, composição farmacêutica, tratamento de combinação para prevenir ou inibir a geração ou atividade de trombina num paciente, método para inibir ou prevenir a geração ou atividade de trombina num paciente, uso de uma composição ou tratamento de combinação, uso de uma composição, uso e kit
GB9917290D0 (en) Pharmaceutical composition